CN102573844A - 射血分数正常心力衰竭的治疗 - Google Patents

射血分数正常心力衰竭的治疗 Download PDF

Info

Publication number
CN102573844A
CN102573844A CN2009801606783A CN200980160678A CN102573844A CN 102573844 A CN102573844 A CN 102573844A CN 2009801606783 A CN2009801606783 A CN 2009801606783A CN 200980160678 A CN200980160678 A CN 200980160678A CN 102573844 A CN102573844 A CN 102573844A
Authority
CN
China
Prior art keywords
patients
exercise
perhexiline
diastolic
heart failure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801606783A
Other languages
English (en)
Chinese (zh)
Inventor
H·阿什拉芬
M·P·弗兰尼克斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heart Metabolics Ltd
Original Assignee
Heart Metabolics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heart Metabolics Ltd filed Critical Heart Metabolics Ltd
Publication of CN102573844A publication Critical patent/CN102573844A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CN2009801606783A 2009-05-20 2009-05-20 射血分数正常心力衰竭的治疗 Pending CN102573844A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2009/050539 WO2010133815A1 (en) 2009-05-20 2009-05-20 Treatment of heart failure with normal ejection fraction

Publications (1)

Publication Number Publication Date
CN102573844A true CN102573844A (zh) 2012-07-11

Family

ID=41213178

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801606783A Pending CN102573844A (zh) 2009-05-20 2009-05-20 射血分数正常心力衰竭的治疗

Country Status (11)

Country Link
US (3) US8440697B2 (https=)
EP (1) EP2432470A1 (https=)
JP (1) JP2012527438A (https=)
CN (1) CN102573844A (https=)
AU (1) AU2009346606B2 (https=)
BR (1) BRPI0924398A2 (https=)
CA (1) CA2816448A1 (https=)
IL (1) IL216362A0 (https=)
MX (1) MX2011012310A (https=)
WO (1) WO2010133815A1 (https=)
ZA (1) ZA201109332B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0405381D0 (en) 2004-03-10 2004-04-21 Univ Wales Medicine A method and means for treating heart failure
GB0908193D0 (en) 2009-05-13 2009-06-24 Albright Patents Treatment of disease state
AU2009346606B2 (en) 2009-05-20 2016-06-02 Heart Metabolics Limited Treatment of heart failure with normal ejection fraction
CN104023725B (zh) 2011-08-16 2019-04-26 卡迪欧拉有限公司 控释制剂
EP2892529A4 (en) * 2012-09-05 2016-01-20 Adelaide Res &Innovation Pty Ltd USES OF (-) - PERHEXILINE
JP2018500365A (ja) 2014-12-22 2018-01-11 カーディオラ ピーティーワイ リミテッド 治療方法
KR20190094214A (ko) 2016-12-15 2019-08-12 백스터 인터내셔널 인코포레이티드 감지된 정맥 파형으로부터 환자 파라미터들을 모니터링하고 결정하기 위한 시스템 및 방법
US11039754B2 (en) 2018-05-14 2021-06-22 Baxter International Inc. System and method for monitoring and determining patient parameters from sensed venous waveform

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1950084A (zh) * 2004-03-10 2007-04-18 心脏代谢有限公司 用于治疗慢性心力衰竭的哌克昔林

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN380695A0 (en) 1995-06-23 1995-07-20 Queen Elizabeth Hospital, The Methods related to the treatment of and isolation of compounds for treatment of ischaemic conditions
US20030162824A1 (en) 2001-11-12 2003-08-28 Krul Elaine S. Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor
CL2004000366A1 (es) 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
NZ550088A (en) 2004-04-06 2009-08-28 Angiogenetics Sweden Ab Angiogenesis-affecting compounds and methods of use thereof
WO2007063012A1 (en) 2005-12-01 2007-06-07 F. Hoffmann-La Roche Ag Heteroaryl substituted piperidine derivatives as l-cpt1 inhibitors
ITRM20060090A1 (it) 2006-02-22 2007-08-23 Sigma Tau Ind Farmaceuti Nuovi composti inibitori cpt a livello del snc come farmaci antidiabetici e o antiobesita
GB0723100D0 (en) * 2007-11-23 2008-01-02 Heart Metabolics Ltd Treatment of HFnEF
GB0908193D0 (en) 2009-05-13 2009-06-24 Albright Patents Treatment of disease state
AU2009346606B2 (en) 2009-05-20 2016-06-02 Heart Metabolics Limited Treatment of heart failure with normal ejection fraction
US20140019207A1 (en) 2012-07-11 2014-01-16 Sap Ag Interactive in-memory based sales forecasting
EP2892529A4 (en) 2012-09-05 2016-01-20 Adelaide Res &Innovation Pty Ltd USES OF (-) - PERHEXILINE
WO2015131231A1 (en) 2014-03-03 2015-09-11 Adelaide Research & Innovation Pty Ltd Methods for using (-)-perhexiline

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1950084A (zh) * 2004-03-10 2007-04-18 心脏代谢有限公司 用于治疗慢性心力衰竭的哌克昔林

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
METRA 等: "Treatment of advanced chronic heart failure with normal left ventricular ejection fraction. Response to the letter by Dr. Martinez-Selles.", 《EUROPEAN JOURNAL OF HEART FAILURE》 *

Also Published As

Publication number Publication date
AU2009346606B2 (en) 2016-06-02
IL216362A0 (en) 2012-01-31
CA2816448A1 (en) 2010-11-25
BRPI0924398A2 (pt) 2019-09-24
US20130210720A1 (en) 2013-08-15
US20100331364A1 (en) 2010-12-30
US9457017B2 (en) 2016-10-04
US9468634B2 (en) 2016-10-18
US20130210719A1 (en) 2013-08-15
US8440697B2 (en) 2013-05-14
ZA201109332B (en) 2012-08-29
AU2009346606A1 (en) 2012-01-19
MX2011012310A (es) 2012-04-11
JP2012527438A (ja) 2012-11-08
WO2010133815A1 (en) 2010-11-25
EP2432470A1 (en) 2012-03-28

Similar Documents

Publication Publication Date Title
Dybro et al. Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy
US9457017B2 (en) Treatment of heart failure
US8697728B2 (en) Perhexiline for use in the treatment of hypertrophic cardiomyopathy (HCM)
Kitzman et al. Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: failure of the Frank-Starling mechanism
Wożakowska-Kapłon et al. Clinical manifestations of slow coronary flow from acute coronary syndrome to serious arrhythmias
Kondo et al. Skeletal muscle pump function is associated with exercise capacity in patients with heart failure
Harada et al. The impact of right ventricular dysfunction on the effectiveness of beta-blockers in heart failure with preserved ejection fraction
Mori et al. Outcomes of Restrictive Cardiomyopathy in Japanese Children―A Retrospective Cohort Study―
Trojnarska et al. Adults with Ebstein's anomaly—cardiopulmonary exercise testing and BNP levels: exercise capacity and BNP in adults with Ebstein's anomaly
Nakaya et al. Changes in Exercise Tolerance over Time in Patients with Transthyretin Amyloidosis Cardiomyopathy Treated with Tafamidis A Preliminary Study
Stolen et al. Myocardial perfusion reserve and oxidative metabolism contribute to exercise capacity in patients with dilated cardiomyopathy
WO2009066085A1 (en) Treatment of heart failure with normal ejection fraction
Lombardo et al. Long-term effects of angiotensin-converting enzyme inhibitors and calcium antagonists on the right and left ventricles in essential hypertension
Stolen et al. Exercise training improves insulin-stimulated myocardial glucose uptake in patients with dilated cardiomyopathy
Nouskas et al. A COVID-19 patient presenting with paroxysmal atrial fibrillation
JP2015147787A (ja) 正常駆出率心不全の治療
Shiga et al. Rationale and Design of the Effect of Ivabradine on Exercise Tolerance in Patients With Chronic Heart Failure (EXCILE-HF) Trial―Protocol for a Multicenter Randomized Controlled Trial―
Omodani et al. Augmented exercise plasma noradrenaline with impaired chronotropic responsiveness in patients with hypertrophic cardiomyopathy
Kitzman et al. Exercise intolerance in patients with heart failure: role of diastolic dysfunction
RU2195179C2 (ru) Способ диагностики жизнеспособного миокарда
Brown Dapagliflozin Regresses Left Ventricular Hypertrophy in People with Type 2 Diabetes
Martellotto et al. Cardiac Resynchronization Therapy Mediated Effects on Exercise Left Ventricular 1 Function, Oxygen Uptake Kinetics, and Peak Oxygen Uptake in Heart Failure 2
Stewart et al. The Effect of Spironolactone on Exercise Tolerance and Arterial Function in Older Patients with HEpEF
Frans Belgian Society of Cardiology 22nd annual scientific meeting
Energy Exercise Physiology

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120711